Growth Hormone Stack
PreclinicalCJC-1295 (with DAC) + Ipamorelin
CJC-1295 with DAC plus Ipamorelin is the most widely prescribed growth hormone secretagogue combination in functional and anti-aging medicine. CJC-1295 with DAC is a modified growth hormone-releasing hormone (GHRH) analog with a Drug Affinity Complex that extends its action to approximately one week. Ipamorelin is a selective growth hormone-releasing peptide (GHRP) that stimulates GH through a different receptor. The combination targets both sides of GH regulation simultaneously. Despite being the most common protocol, no published study has tested these two compounds together. Here is what the research shows for each component.
Science simplified
Your pituitary gland releases growth hormone in pulses. This stack targets the two main switches that control those pulses. CJC-1295 with DAC tells the pituitary to make more GH (the "gas pedal"), while Ipamorelin amplifies the release signal at a different receptor (the "amplifier"). The DAC modification keeps CJC-1295 active for about a week instead of minutes. The idea is that activating both switches produces more GH than either alone. This has never been tested.
Best researched for
GH elevation · IGF-1 increase · each component individually
Evidence stage
Zero combination data · individual components L2
Approval status
Not FDA-approved · DAC variant likely Category 2
0
Indexed Studies
Preclinical
Evidence Level
None
Human Trial Data
Research
Approval Status
PSI OVERVIEW
This is likely the single most prescribed peptide combination in the United States. The pharmacological rationale is elegant: CJC-1295 with DAC provides sustained GHRH signaling (telling the pituitary to produce GH), while ipamorelin provides selective ghrelin receptor activation (amplifying the GH release pulse). Together, they aim to produce higher, more sustained GH elevation than either alone. PSI rates this combination at the Animal Studies tier — not because the logic is wrong, but because no published study has ever tested it. The individual components are each at the Animal Studies tier. The combination is assumed to be additive or synergistic based on the dual-receptor rationale, but this has never been measured. It is the most widely used untested peptide protocol in clinical practice.
Mechanism of Action
In everyday terms: Your body releases growth hormone in pulses, controlled by two main signals. One signal says "make GH" (GHRH pathway) and the other says "release it now" (ghrelin pathway). This stack activates both at the same time. CJC-1295 with DAC keeps the "make GH" signal on for about a week. Ipamorelin triggers the "release it now" signal cleanly, without raising cortisol or prolactin. The theory is that both signals together produce a bigger GH response.
CJC-1295 with DAC is a 30-amino-acid GHRH analog conjugated to a Drug Affinity Complex (maleimidopropionic acid) that binds albumin in vivo. This extends the half-life from approximately 6 minutes (native GHRH) to 6–8 days, providing sustained GHRH receptor activation and continuous stimulation of GH synthesis at the pituitary. Ipamorelin is a pentapeptide growth hormone-releasing peptide (GHRP) that activates the ghrelin receptor (GHSR-1a) to trigger GH release. Unlike other GHRPs (GHRP-2, GHRP-6, hexarelin), ipamorelin is highly selective — it does not significantly elevate cortisol, ACTH, or prolactin.
What is this stack being studied for?
No study has tested this combination. Evidence ratings reflect the stack as a whole. See individual compound pages for component-level evidence.
Growth Hormone Optimization
Animal StudiesCJC-1295 with DAC provides sustained GHRH signaling over ~7 days. Ipamorelin selectively stimulates GH release without cortisol or prolactin elevation. The combination targets both GHRH and GHSR receptors simultaneously. No combination study exists.
Body Composition
PreclinicalGH elevation from either component individually trends toward improved lean mass and decreased fat mass. Whether the combination produces clinically meaningful body composition changes is not established in any published trial.
Anti-Aging & Recovery
PreclinicalThe rationale is that sustained elevated GH levels may improve recovery, sleep, skin quality, and energy. These outcomes are commonly reported by patients but not measured in controlled studies of this combination.
Sleep Quality
PreclinicalGH secretagogues generally improve slow-wave sleep through enhanced GH pulsatility during sleep. Neither component has been studied specifically for sleep as a primary endpoint, and the combination has no sleep data.
PSI Verdict
Supported by evidence
CJC-1295 with DAC extends GHRH signaling to approximately 7 days via albumin binding (DAC mechanism). Ipamorelin selectively stimulates GH release without cortisol, prolactin, or ACTH elevation. The dual-receptor rationale (GHRH + GHSR) is pharmacologically sound. Both components individually elevate GH and IGF-1 in published human data.
Not yet established
Whether the combination produces greater GH elevation than either component alone. Whether combined use is safe — no combination safety data exists. Whether the DAC variant's sustained release interacts with ipamorelin's pulsatile mechanism in a beneficial way. The optimal timing, dose ratio, and frequency of the combination. Despite being the most prescribed peptide stack in functional medicine, zero published comparison data exists.
Confidence level
Low-to-moderate. The pharmacological logic is sound but untested. L2 reflects the individual component evidence without combination validation. The gap between clinical adoption and published evidence is the largest in the PSI registry for any protocol. See: CJC-1295, Ipamorelin.
Stack Components
Molecular data for each component.
Research Evidence
No published research exists on this combination. The evidence below summarizes individual component data and the theoretical rationale for combining them.
CJC-1295 with DAC produces sustained IGF-1 elevation for 6–8 days after a single injection in published human pharmacokinetic studies
This is the key advantage of the DAC variant: weekly rather than daily dosing. The sustained elevation is well-documented.
Ipamorelin is the most selective GHRP — it stimulates GH without raising cortisol, ACTH, or prolactin
This selectivity distinguishes ipamorelin from GHRP-2, GHRP-6, and hexarelin, which all elevate cortisol and/or prolactin.
The dual-receptor rationale (GHRH + GHSR) is supported by decades of endocrine physiology research
GHRH and ghrelin act through distinct intracellular signaling cascades at the pituitary somatotroph. Their combination is theoretically synergistic.
This is the most prescribed peptide combination in US functional medicine despite zero combination studies
The gap between clinical adoption and published evidence is the largest for any protocol in the PSI registry.
CJC-1295 with DAC is expected to remain on the FDA Category 2 restricted list
This regulatory distinction from the no-DAC version may affect availability. Ipamorelin is expected to return to Category 1.
Safety Profile
No safety data exists for the CJC-1295 (with DAC) + Ipamorelin combination. Each component has limited individual human safety data. CJC-1295 with DAC is on the FDA Category 2 restricted list and is expected to remain restricted. Ipamorelin is expected to return to Category 1. Combining two investigational GH secretagogues may produce additive hormonal effects — IGF-1 monitoring is recommended.
Comparison: GH Secretagogue Options
Multiple GH secretagogue options exist with different mechanisms, dosing schedules, regulatory statuses, and evidence depths. The choice depends on specific goals, regulatory access, and tolerance for dosing complexity.
Frequently Asked Questions
Questions to Ask Your Doctor
If you are considering discussing this combination with a healthcare provider, these questions can help start an informed conversation.
Explore Related Research
Side-by-side research comparisons with related compounds.
How to Choose
Decision guidance based on existing evidence — not a recommendation.
Looking for a physician experienced with peptide therapy?
Every physician in the PSI directory is individually verified for active licensure, board certification, and clinical peptide experience.
Browse the PSI Physician DirectoryMedical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.